SHS_543053 YUEK CNOV 14132
A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing's disease or acromegaly
The study aims to demonstrate that pasireotide-induced hyperglycemia can be effectively and safely managed in majority of patients, including those with diabetes at start of pasireotide treatment.
Patients greater than or equal to 18 years old
Confirmed diagnosis of Cushing's disease or acromegaly
Patients who require surgical intervention
Patients receiving DPP-4 inhibitors or GLP-1 receptor agonists within 4 weeks prior to study entry
HbA1c > 10% at screening
Known hypersensitivity to somatostatin analogues
Other protocol-defined inclusion/exclusion criteria may apply.
Kevin Yuen, M.D.